Moderna Inc (NASDAQ:MRNA) announced Friday that the European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate, bringing its confirmed order commitment to 160 million doses.
The first deliveries of mRNA-1273 to European countries from Modena’s dedicated European supply chain are expected to commence early in 2021 following regulatory approval by the European Medicines Agency (EMA) scientific committee for human medicines (CHMP) and the European Commission’s Decision regarding the Conditional Marketing Authorisation (CMA) for the vaccine. The CHMP meeting is planned for January 6, 2021.
Moderna CEO said Stéphane Bancel, “We appreciate the confidence in Moderna and mRNA-1273, our COVID-19 vaccine candidate, demonstrated by today’s increased supply agreement with the European Commission
“As we shift our focus now to prepare for the delivery of our vaccine candidate, pending a positive opinion from the EMA and other regulators, we remain committed to working with governments and partners globally to address this pandemic.”
Moderna has also confirmed the following supply agreements of committed orders totaling more than 470 million doses:
• United States: 200 million doses with option for an additional 300 million doses
• European Union: 160 million doses
• Japan: 50 million doses
• Canada: 40 million doses with option for an additional 16 million doses
• Switzerland: 7.5 million doses
• United Kingdom: seven million doses
• Israel: six million doses
• Qatar
• Singapore
MRNA shares retreated $6.44, or 4.5%, to $137.57.